Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma Edwin Pun HuiVivian W. Y. LuiAnthony T. C. Chan PRECLINICAL STUDIES 15 May 2010 Pages: 1123 - 1131
Combined anticancer effects of sphingosine kinase inhibitors and sorafenib Vladimir BeljanskiChristian KnaakCharles D. Smith PRECLINICAL STUDIES 18 May 2010 Pages: 1132 - 1142
LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells Raquel C. MaiaFlavia C. VasconcelosPaulo R. R. Costa PRECLINICAL STUDIES 25 May 2010 Pages: 1143 - 1155
Dequalinium induces apoptosis in peripheral blood mononuclear cells isolated from human chronic lymphocytic leukemia Lucia PajueloEva CalviñoPilar Sancho PRECLINICAL STUDIES 05 June 2010 Pages: 1156 - 1163
Discrepancy between in vitro and in vivo antitumor effect of a new platinum(II) metallointercalator Johnny MorettoBruno ChauffertFlorence Bouyer PRECLINICAL STUDIES 10 June 2010 Pages: 1164 - 1176
Q39, a quinoxaline 1,4-Di-N-oxide derivative, inhibits hypoxia-inducible factor-1α expression and the Akt/mTOR/4E-BP1 signaling pathway in human hepatoma cells Qinjie WengJun ZhangBo Yang PRECLINICAL STUDIES 05 June 2010 Pages: 1177 - 1187
Inhibition of mouse embryonic carcinoma cell growth by lidamycin through down-regulation of embryonic stem cell-like genes Oct4, Sox2 and Myc Hong-Ying ZhenQi-Hua HeLi Shen PRECLINICAL STUDIES 02 July 2010 Pages: 1188 - 1197
Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination Fumiko TaguchiYasuo KoderaFumiaki Koizumi PRECLINICAL STUDIES 08 June 2010 Pages: 1198 - 1205
The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells Wei-Gang TongZeev EstrovAlessandra Ferrajoli PRECLINICAL STUDIES 09 June 2010 Pages: 1206 - 1212
Cytotoxicity in human cancer cells and mitochondrial dysfunction induced by a series of new copper(I) complexes containing tris(2-cyanoethyl)phosphines Alessandro ZanellaValentina GandinCristina Marzano PRECLINICAL STUDIES 22 June 2010 Pages: 1213 - 1223
The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines Daniel R. BudmanJulia TaiVeena John PRECLINICAL STUDIES 09 June 2010 Pages: 1224 - 1229
Anti-tumour effects of xanthone derivatives and the possible mechanisms of action Quan-Guan SuYan LiuLi-Jian Xian PRECLINICAL STUDIES 26 June 2010 Pages: 1230 - 1240
Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells Vivian Wai Yan LuiCecilia Pik Yuk LauTony Shu Kam Mok PRECLINICAL STUDIES 23 June 2010 Pages: 1241 - 1252
Evaluation of new iodinated acridine derivatives for targeted radionuclide therapy of melanoma using 125I, an Auger electron emitter Maryline GardetteJanine PaponNicole Moins PRECLINICAL STUDIES 22 June 2010 Pages: 1253 - 1263
Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis Federica ServidaDaniele LecisFrancesco Onida PRECLINICAL STUDIES 08 July 2010 Pages: 1264 - 1275
The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells Jin-Jian LuSi-Meng ChenLing-Hua Meng PRECLINICAL STUDIES 07 July 2010 Pages: 1276 - 1283
Modulation of P-gp expression by lapatinib Gráinne DunneLaura BreenRobert O’Connor PRECLINICAL STUDIES 06 July 2010 Pages: 1284 - 1293
Cytostatic activity of the duplex drug linking 2′-deoxy-5-fluorouridine (5FdU) with 3′-C-ethynylcytidine (ECyd) against gastric adenocarcinoma cell lines Jürgen WeinreichSarah SchottHerbert Schott PRECLINICAL STUDIES 02 July 2010 Pages: 1294 - 1302
Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status Francesca BuontempoTulin ErsahinMaria Luca Neri PRECLINICAL STUDIES 14 July 2010 Pages: 1303 - 1313
Pankiller effect of prolonged exposure to menadione on glioma cells: potentiation by vitamin C Marina F. VitaNivedita NagacharJuan Sebastian Yakisich PRECLINICAL STUDIES Open access 13 July 2010 Pages: 1314 - 1320
Cellular uptake and cytoplasm / DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116 Thititip TippayamontriRami KotbLéon Sanche PRECLINICAL STUDIES 24 July 2010 Pages: 1321 - 1327
Sonodynamic and photodynamic mechanisms of action of the novel hypocrellin sonosensitizer, SL017: mitochondrial cell death is attenuated by 11, 12-epoxyeicosatrienoic acid Haitham E. El-SikhryGerald G. MillerJohn M. Seubert PRECLINICAL STUDIES 30 July 2010 Pages: 1328 - 1336
YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway Chin-Chuan HungHorng-Huei Liou PRECLINICAL STUDIES 31 July 2010 Pages: 1337 - 1346
Protoapigenone, a natural derivative of apigenin, induces mitogen-activated protein kinase-dependent apoptosis in human breast cancer cells associated with induction of oxidative stress and inhibition of glutathione S-transferase π Wen-Ying ChenYu-An HsiehChin-Chung Wu PRECLINICAL STUDIES 05 August 2010 Pages: 1347 - 1359
Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study Qing ZhangHong ChenZhong-yang Shen SPECIAL ISSUE ARTICLE 02 August 2011 Pages: 1360 - 1369
Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics Michael A. TortoriciMelvin TohYazdi K. Pithavala PHASE I STUDIES Open access 02 July 2010 Pages: 1370 - 1380
Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT Christopher R. GarrettDomenico CoppolaSaïd M. Sebti PHASE I STUDIES 20 July 2010 Pages: 1381 - 1389
A phase I study of topotecan and gemcitabine in advanced solid tumors Derek S. SernaTanios Bekaii-SaabEric H. Kraut PHASE I STUDIES 25 June 2010 Pages: 1390 - 1394
Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study Patricia LoRussoAnthony F. ShieldsQi Liu PHASE I STUDIES 06 July 2010 Pages: 1395 - 1405
Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas Ramón SalazarRuth PlummerAlan Hilary Calvert PHASE I STUDIES 10 July 2010 Pages: 1406 - 1413
Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs Nicolas PenelAntoine AdenisJacques Bonneterre PHASE I STUDIES 09 July 2010 Pages: 1414 - 1419
A phase I study of the vitamin D3 analogue ILX23-7553 administered orally to patients with advanced solid tumors Rajul K. JainDonald L. TrumpRamesh K. Ramanathan PHASE I STUDIES 27 July 2010 Pages: 1420 - 1425
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies Elisabeth I. HeathPatricia LoRussoChandra P. Belani PHASE I STUDIES 03 August 2010 Pages: 1426 - 1431
Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium Deborah A. BradleyStephanie DaignaultMaha Hussain PHASE II STUDIES 25 March 2010 Pages: 1432 - 1440
Oral enzastaurin in prostate cancer: A two-cohort phase II trial in patients with PSA progression in the non-metastatic castrate state and following docetaxel-based chemotherapy for castrate metastatic disease Robert DreicerJorge GarciaDerek Raghavan PHASE II STUDIES 06 April 2010 Pages: 1441 - 1448
Phase II study of sunitinib as second-line treatment for advanced gastric cancer Yung-Jue BangYoon-Koo KangAlberto Sobrero PHASE II STUDIES Open access 12 May 2010 Pages: 1449 - 1458
Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study Emilio Esteban GonzalezNoemi VillanuevaAngel J. Lacave PHASE II STUDIES 13 May 2010 Pages: 1459 - 1464
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC) Michael R. HarrisonNoah M. HahnGlenn Liu PHASE II STUDIES 25 May 2010 Pages: 1465 - 1474
A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma Manish A. ShahDerek G. PowerDavid P. Kelsen PHASE II STUDIES 25 June 2010 Pages: 1475 - 1481
A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer Margarette BryanE. Dianne PulteRobert Wieder PHASE II STUDIES 02 July 2010 Pages: 1482 - 1487
Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer Takashi SasakiHiroyuki IsayamaKazuhiko Koike PHASE II STUDIES 06 July 2010 Pages: 1488 - 1493
Reactivation of tuberculosis during temsirolimus therapy Romain CoriatOlivier MirFrançois Goldwasser SHORT REPORT 10 July 2010 Pages: 1494 - 1496
VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption Stanislas RopertOlivier VignauxFrançois Goldwasser SHORT REPORT 30 July 2010 Pages: 1497 - 1499
Bevacizumab-induced small bowel perforation in a patient with breast cancer without intraabdominal metastases Edouard LecarpentierLamia OuaffiNicolas Veyrie SHORT REPORT 31 July 2010 Pages: 1500 - 1503
In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinoma Ying Yi ChenGraeme J. FinlayBruce C. Baguley SHORT REPORT 10 August 2010 Pages: 1504 - 1510
Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma Charline GomoRomain CoriatBenoit Blanchet SHORT REPORT 13 August 2010 Pages: 1511 - 1514
Letter to the editor: “Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer” M. J. Molina-GarridoCarmen Guillén-Ponce LETTER TO THE EDITOR 16 December 2010 Pages: 1515 - 1516
Erratum to: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium Deborah A. BradleyStephanie DaignaultMaha Hussain Erratum 10 August 2010 Pages: 1517 - 1518
